Peptide–Antibody Fusions Engineered by Phage Display Exhibit an Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

Small and Simple, yet Sturdy: Conformationally Constrained Peptides with Remarkable Properties

(2021) Krištof Bozovičar et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies

(2021) Renhong Yan et al.   CELL RESEARCH

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

(2021) Raoul De Gasparo et al.   NATURE

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

(2021) Bryan E. Jones et al.   Science Translational Medicine

Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies

(2021) Xing Zhu et al.   PLOS BIOLOGY

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations

(2021) Shane Miersch et al.   JOURNAL OF MOLECULAR BIOLOGY

Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers

(2021) Edurne Rujas et al.   Nature Communications

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

(2021) Rachel E Sanborn et al.   Journal for ImmunoTherapy of Cancer

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

(2021) Prerna Arora et al.   Cellular & Molecular Immunology

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

(2021) Alice Cho et al.   NATURE

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

(2020) Renhong Yan et al.   SCIENCE

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples

(2020) Alessandro Manenti et al.   JOURNAL OF MEDICAL VIROLOGY

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

(2020) Yan Wu et al.   SCIENCE

Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice

(2020) James Brett Case et al.   Cell Host & Microbe

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

(2020) James Brett Case et al.   Cell Host & Microbe

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

(2020) Lihong Liu et al.   NATURE

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

(2020) Daming Zhou et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

(2020) Johanna Hansen et al.   SCIENCE

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

(2020) Shuo Du et al.   CELL

A persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual

(2020) Francesca Caccuri et al.   Journal of Translational Medicine

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

(2020) Longxing Cao et al.   SCIENCE

De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein

(2020) Sebastian Pomplun et al.   ACS Central Science

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

(2019) Karen A. Autio et al.   CLINICAL CANCER RESEARCH

Biophysical properties of the clinical-stage antibody landscape

(2017) Tushar Jain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapid isolation of peptidic inhibitors of the solute carrier family transporters OATP1B1 and OATP1B3 by cell-based phage display selections

(2016) Yuko Arita et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Probody therapeutics for targeting antibodies to diseased tissue

(2014) Krishna R Polu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine